Price movement over the last 24 hours
Alexandria Real Estate Equities Inc vs McKesson Corporation — how do they compare? Alexandria Real Estate Equities Inc trades at $47.74 (market cap $8.34B), while McKesson Corporation trades at $809.88 (market cap $94.36B). The key difference: McKesson Corporation is far larger — about 11.3× Alexandria Real Estate Equities Inc's market cap, and Alexandria Real Estate Equities Inc pays the higher dividend (6.02%). Which is the better fit depends on your goals.
| ARE | MCK | |
|---|---|---|
Market Cap | $8.34B | $94.36B |
Sector | Real Estate | Health |
52-Week High | $87.45 | $995.69 |
52-Week Low | $40.41 | $659.01 |
Enterprise Value | $20.80B | $99.00B |
Dividend Yield | 6.02% | 0.41% |
Signals from Pluang's Aura AI — not financial advice
Alexandria Real Estate Equities (ARE) trades at $47.88, down 1.3% on the day, with a bearish technical signal and mixed fundamentals. The stock shows a high P/E of 102.99 and negative net income margin of -37.09%, though it maintains a strong gross margin of 67.76% and positive operating cash flow. Recent news highlights corporate responsibility initiatives and a declared dividend of $0.72 per share for Q2 2026.
The outlook is cautious due to profitability challenges and elevated debt, but analyst consensus suggests moderate upside to a $51.00 price target. Key risks include sustained negative earnings and interest rate sensitivity, while institutional sentiment leans neutral with 58.33% hold ratings.
McKesson (MCK) trades at $805.96, up 1.66% with strong bullish momentum near its pivot point of $799. The stock shows consistent earnings beats, with Q1 2026 EPS of $11.69 exceeding expectations, and revenue growth accelerating to $359.05B in 2025. Analyst sentiment is overwhelmingly positive with an 80% buy rating and a $932.83 consensus price target, while recent corporate developments include a strategic investment in Medical-Surgical Solutions with Apollo Funds.
The outlook remains favorable given robust cash flow generation and expanding profitability, though risks include policy uncertainties and high leverage. Upside potential is supported by valuation discounts relative to sector peers and continued execution in specialty pharma and oncology services.
Trailing returns across standard periods
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.
Read more on ARE →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →